Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00746252 · ClinicalTrials.gov registry record · NA
Side Effect Study of Antipsychotic Medicines to Treat Childhood Bipolar Disorder
A NA study, sponsored by University of Maryland, Baltimore.
- Terminated
- Registry status
- NA
- Development phase
- 5
- Enrollment target
NCT00746252 is a NA study that was terminated before completion, run by University of Maryland, Baltimore. The registered enrollment target is 5 participants.
The verdict
NCT00746252, a NA study, was terminated before completion, sponsored by University of Maryland, Baltimore.
- TERMINATED
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to learn more about weight gain and related side effects when children are treated with antipsychotic medicine for mood disorders.
Interventions
- DRUG risperidone
- DRUG aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2008-06 |
| Est. Completion | 2010-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00746252
The ClinicalTrials.gov registry entry for NCT00746252 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which risperidone is the first listed.
NCT00746252 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00746252 about?
NCT00746252 is a clinical study titled "Side Effect Study of Antipsychotic Medicines to Treat Childhood Bipolar Disorder". The purpose of this study is to learn more about weight gain and related side effects when children are treated with antipsychotic medicine for mood disorders.
What is the current status of trial NCT00746252?
This trial is currently terminated. It is a NA study. The enrollment target is 5 participants. The study started on 2008-06. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00746252?
The interventions under investigation include: risperidone (DRUG), aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00746252?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.